Margaret Humphries

1.8k total citations
15 papers, 1.3k citations indexed

About

Margaret Humphries is a scholar working on Genetics, Molecular Biology and Epidemiology. According to data from OpenAlex, Margaret Humphries has authored 15 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 9 papers in Molecular Biology and 5 papers in Epidemiology. Recurrent topics in Margaret Humphries's work include Virus-based gene therapy research (10 papers), Viral Infectious Diseases and Gene Expression in Insects (5 papers) and Herpesvirus Infections and Treatments (4 papers). Margaret Humphries is often cited by papers focused on Virus-based gene therapy research (10 papers), Viral Infectious Diseases and Gene Expression in Insects (5 papers) and Herpesvirus Infections and Treatments (4 papers). Margaret Humphries collaborates with scholars based in United States, Ireland and United Kingdom. Margaret Humphries's co-authors include Terence R. Flotte, Jeffrey D. Chulay, Mark Brantly, Roberto Calcedo, L. Terry Spencer, Barry J. Byrne, Christian Mueller, Farshid N. Rouhani, James M. Wilson and Thomas J. Conlon and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Ophthalmology and Investigative Ophthalmology & Visual Science.

In The Last Decade

Margaret Humphries

13 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Margaret Humphries United States 10 893 863 286 156 155 15 1.3k
Giridhara R. Jayandharan India 27 1.6k 1.8× 1.2k 1.4× 232 0.8× 154 1.0× 160 1.0× 83 2.3k
Kenneth H. Warrington United States 17 1.4k 1.6× 1.5k 1.7× 277 1.0× 239 1.5× 229 1.5× 20 1.9k
Scott Loiler United States 13 722 0.8× 781 0.9× 140 0.5× 130 0.8× 135 0.9× 20 1.2k
Helena Costa Verdera France 7 917 1.0× 535 0.6× 219 0.8× 87 0.6× 104 0.7× 10 1.2k
Samuel L. Murphy United States 13 1.5k 1.7× 1.2k 1.4× 528 1.8× 247 1.6× 181 1.2× 27 2.0k
Sally Fuess United States 13 1.7k 1.9× 1.6k 1.8× 275 1.0× 229 1.5× 310 2.0× 14 2.2k
Denise E. Sabatino United States 25 1.8k 2.0× 1.8k 2.1× 739 2.6× 279 1.8× 180 1.2× 53 2.8k
Julio Sanmiguel United States 21 1.1k 1.3× 1.1k 1.3× 263 0.9× 264 1.7× 294 1.9× 28 1.7k
David‐Alexandre Gross France 23 898 1.0× 529 0.6× 458 1.6× 88 0.6× 90 0.6× 41 1.7k
Johannes C.M. van der Loo United States 18 868 1.0× 731 0.8× 418 1.5× 94 0.6× 58 0.4× 32 1.7k

Countries citing papers authored by Margaret Humphries

Since Specialization
Citations

This map shows the geographic impact of Margaret Humphries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret Humphries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret Humphries more than expected).

Fields of papers citing papers by Margaret Humphries

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret Humphries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret Humphries. The network helps show where Margaret Humphries may publish in the future.

Co-authorship network of co-authors of Margaret Humphries

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret Humphries. A scholar is included among the top collaborators of Margaret Humphries based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret Humphries. Margaret Humphries is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Pennesi, Mark E., Richard G. Weleber, Paul Yang, et al.. (2018). Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy. Human Gene Therapy. 29(12). 1428–1437. 50 indexed citations
2.
Mueller, Christian, Gwladys Gernoux, Alisha M. Gruntman, et al.. (2017). 5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency. Molecular Therapy. 25(6). 1387–1394. 82 indexed citations
3.
Weleber, Richard G., Mark E. Pennesi, David J. Wilson, et al.. (2016). Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood–Onset Retinal Dystrophy. Ophthalmology. 123(7). 1606–1620. 160 indexed citations
4.
Mueller, Christian, Jeffrey D. Chulay, Noel G. McElvaney, et al.. (2016). 24. Sustained Expression with Partial Correction of Neutrophil Defects 5 Years After Intramuscular rAAV1 Gene Therapy for Alpha-1 Antitrypsin Deficiency. Molecular Therapy. 24. S11–S12. 2 indexed citations
5.
Weleber, Richard G., David J. Wilson, Dawn Peters, et al.. (2013). Treatment of Patients with Leber Congenital Amaurosis Type 2 with an AAV Vector Expressing RPE65. Investigative Ophthalmology & Visual Science. 54(15). 5964–5964. 1 indexed citations
6.
Flotte, Terence R., Bruce C. Trapnell, Margaret Humphries, et al.. (2011). Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing α 1 -Antitrypsin: Interim Results. Human Gene Therapy. 22(10). 1239–1247. 265 indexed citations
7.
Flotte, Terence R., Margaret Humphries, Brenna Carey, et al.. (2011). Phase 2 Clinical Trial Of A Recombinant Adeno-Associated Virus (RAAV) Alpha-1 Antitrypsin (AAT) Gene Therapy Vector. A2428–A2428.
8.
Chulay, Jeffrey D., Darby L. Thomas, David R. Knop, et al.. (2010). Preclinical Evaluation of a Recombinant Adeno-Associated Virus Vector Expressing Human Alpha-1 Antitrypsin Made Using a Recombinant Herpes Simplex Virus Production Method. Human Gene Therapy. 22(2). 155–165. 48 indexed citations
9.
Brantly, Mark, Jeffrey D. Chulay, Lili Wang, et al.. (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proceedings of the National Academy of Sciences. 106(38). 16363–16368. 257 indexed citations
10.
Brantly, Mark, L. Terry Spencer, Margaret Humphries, et al.. (2006). Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Serotype 2 α 1-Antitrypsin (AAT) Vector in AAT-Deficient Adults. Human Gene Therapy. 17(12). 1177–1186. 141 indexed citations
11.
Flotte, Terence R., Mark Brantly, L. Terry Spencer, et al.. (2004). Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults. Human Gene Therapy. 15(1). 93–128. 112 indexed citations
12.
Flotte, Terence R., Pamela L. Zeitlin, Thomas C. Reynolds, et al.. (2003). Phase I Trial of Intranasal and Endobronchial Administration of a Recombinant Adeno-Associated Virus Serotype 2 (rAAV2)-CFTR Vector in Adult Cystic Fibrosis Patients: A Two-Part Clinical Study. Human Gene Therapy. 14(11). 1079–1088. 180 indexed citations
13.
Flotte, Terence R., Pamela L. Zeitlin, Richard Daifuku, et al.. (1997). A Phase I Study of AAV-CFTR Administration in Adult Cystic Fibrosis Patients 1794. Pediatric Research. 41. 301–301. 1 indexed citations
14.
Bartunek, Jean M., Danna Greenberg, Margaret Humphries, & Barbara Parmer Davidson. (1996). PARTICIPATION, COMPLEXITY OF UNDERSTANDING, AND THE ASSESSMENT OF ORGANIZATIONAL CHANGE.. Academy of Management Proceedings. 1996(1). 259–263. 3 indexed citations
15.
Humphries, Margaret, et al.. (1977). ABSORPTION OF LEAD AND CARBON MONOXIDE IN SYDNEY TRAFFIC POLICEMEN. The Medical Journal of Australia. 1(13). 437–439. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giridhara R. Jayandharan Breakdown of academic impact, for papers by Kenneth H. Warrington Breakdown of academic impact, for papers by Scott Loiler Breakdown of academic impact, for papers by Helena Costa Verdera Breakdown of academic impact, for papers by Samuel L. Murphy Breakdown of academic impact, for papers by Sally Fuess Breakdown of academic impact, for papers by Denise E. Sabatino Breakdown of academic impact, for papers by Julio Sanmiguel Breakdown of academic impact, for papers by David‐Alexandre Gross Breakdown of academic impact, for papers by Johannes C.M. van der Loo
Rankless by CCL
2026